Navigation Links
Drug for Acute Respiratory Distress May Do More Harm Than Good: Study
Date:12/12/2011

SUNDAY, Dec. 11 (HealthDay News) -- A study assessing intravenous infusion of the drug salbutamol in patients with acute respiratory distress syndrome was halted because the treatment did not improve patient outcomes and was associated with an increased risk of death, researchers say.

Acute respiratory distress syndrome (ARDS) occurs in about 14 percent of patients who require being placed on mechanical ventilation. The death rate among patients with ARDS is high -- 40 to 60 percent -- and survivors have a substantial decrease in their quality of life.

However, "routine use of [beta-2] agonist therapy in mechanically ventilated patients with ARDS cannot be recommended," the researchers wrote in an article published in the Dec. 12 online edition of The Lancet.

The British study included 326 patients who received either salbutamol (also known as albuterol) or a placebo within 72 hours of developing ARDS, and the treatment continued for up to seven days. But the study was stopped after 55 (34 percent) of the 161 patients in the salbutamol group died, compared with 38 (23 percent) of the 163 patients in the placebo group.

Overall, the death rate was 47 percent higher in the salbutamol group than in the placebo group, the report indicated.

In addition, patients in the salbutamol group had fewer ventilator-free days and organ failure-free days than those in the placebo group.

"Our findings show that intravenous salbutamol given to patients with early ARDS significantly increased 28-day mortality, and reduced ventilator-free days and duration of organ support compared with those given placebo," Fang Gao Smith and Gavin Perkins of the University of Warwick, and colleagues, explained in a journal news release.

The authors added that the therapy was "poorly tolerated" by patients because it was linked to heart rhythm abnormalities and lactic acidosis (a dangerous buildup of lactic acid in the blood). "These findings were unexpected," the researchers noted.

The findings of the cancelled study may be sufficient to change treatment of patients with ARDS, Dr. B. Taylor Thompson, of Massachusetts General Hospital and Harvard Medical School, wrote in an accompanying editorial.

"[Beta-2] agonist treatment in patients with ARDS should be limited to the treatment of clinically important reversible airway obstruction and should not be part of routine care," Thompson recommended.

More information

The U.S. National Heart, Lung, and Blood Institute has more about acute respiratory distress syndrome.

-- Robert Preidt

SOURCE: The Lancet, news release, Dec. 11, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Few With Acute Kidney Injury See Specialists, Study Finds
2. TAST 2011 -- Thrombolysis and Acute Stroke Treatment in 2011: Preparing for the next decade
3. Dendritic cells protect against acute pancreatitis
4. FDA funds Rochester researchers to give chronic and acute pain clinical trials a makeover
5. Unsaturated fat breakdown leads to complications of acute pancreatitis in obese patients
6. Miriam Hospital researchers pilot new acute hepatitis C screening strategy for HIV-infected patients
7. Death Rate Higher in Minorities With Acute Leukemia
8. Regional differences in the care of acute stroke patients
9. Alcohol consumption in relation to acute pancreatitis
10. Drinking just 1 measure of spirits increases the risk of acute pancreatitis
11. $12 million NIH grant to study acute lung injury
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug for Acute Respiratory Distress May Do More Harm Than Good: Study
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one of the ... 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs ... across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... ... 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from around the ... - 23 in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive ... Beaver Creek, hosting over 60 faculty members and addressing unmet needs of the NET ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... last long after their final treatments. Physician researchers at The Marcus Institute ... a mind-body therapy, for efficacy in reducing symptoms of traumatic stress in cancer ...
(Date:2/16/2017)... ... February 16, 2017 , ... Doctors on Liens is proud ... their network through his work at BKP Chiropractic in Lancaster . ... degree from Canada’s prestigious International Baccalaureate Program, Dr. Raj went on to open ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , February 17, 2017 Cryoablation, Electrical, ... The global ablation technologies market is expected to grow ... from 2022-2027. The market is expected to grow at a CAGR ... $3.3bn in 2016, and $9.05bn in 2026. ... How this report will benefit you ...
(Date:2/17/2017)... , February 17, 2017 According to ... Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of ... to 2021" published by MarketsandMarkets, the market is expected to reach ... at a CAGR of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... 17, 2017 Theravance Biopharma, Inc. (NASDAQ: ... "Company") today announced the presentation of positive clinical ... administered pan-Janus kinase (JAK) inhibitor designed to be ... of the European Crohn,s and Colitis Organization (ECCO). ... data from its completed Phase 1 study of ...
Breaking Medicine Technology: